Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica

NCT ID: NCT06558357

Last Updated: 2024-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

210 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Polymyalgia Rheumatica is difficult to diagnostic because symptoms are non specific and many diseases can be differential diagnosis (cancer, infections, others rheumatisms...).

PET-CT is more often used to help for diagnostic of inflammatory disease, and particularly inflammatory rheumatism.

Some scores have been described to harmonize the diagnosis of Polymyalgia rheumatica.

The aim of this study is to evaluate the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and compared with others inflammatories diseases such as ankylosing spondylarthritis.

This is a multicentric retrospective study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Rheumatism 18-FDG Positron-emission Tomography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Having 18-FDG PET-CT between 2012 and 2024
* Diagnosis of inflammatory rheumatism by specialist doctor
* Adult without opposition to use there data for research
* Affiliate to social security system

Exclusion Criteria

* Refusal participation
* Patient under juridic protection
Minimum Eligible Age

18 Years

Maximum Eligible Age

110 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Brest

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Solène QUERELLOU

Role: STUDY_DIRECTOR

CHU Brest

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Brest

Brest, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Solène QUERELLOU

Role: CONTACT

0298223080 ext. +33

Chloé QUERE

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

29BRC24.0172 - RHUMATEP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.